» Articles » PMID: 15492562

Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma

Overview
Journal Ann Surg
Specialty General Surgery
Date 2004 Oct 20
PMID 15492562
Citations 286
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To review recurrence patterns in completely resected gastric adenocarcinoma.

Summary Background Data: Despite improvements in the surgical treatment of gastric adenocarcinoma, recurrence rates remain high in patients with advanced stage disease. Understanding the timing and patterns of recurrence is essential to develop effective adjuvant treatment strategies.

Methods: A retrospective review of a prospectively maintained gastric cancer database was carried out. The timing and pattern of recurrence were reviewed. Univariate and multivariate analyses were performed to identify factors predictive of recurrence patterns.

Results: From July 1985 through June 2000, 1172 patients underwent an R0 resection. Of these, 496 (42%) had recurrence and complete data on recurrence could be obtained in 367 patients (74%). Among the documented recurrences, 79% were detected within 2 years of operation. Locoregional sites were involved as any part of the recurrence pattern in 199 patients (54%). Distant sites were involved as any part of the recurrence in 188 patients (51%) and peritoneal recurrence was detected as any part of the recurrence in 108 patients (29%). On multivariate analysis, peritoneal recurrence was associated with female gender, advanced T-stage, and distal and diffuse type tumors; locoregional recurrence was associated with male gender and proximal location; distant recurrence was associated with proximal location, early T stage, and intestinal type tumors. The median time to death from the time of recurrence was 6 months.

Conclusions: Recurrence after complete resection of gastric adenocarcinoma usually occurs within 2 years and is rapidly fatal. Patterns of recurrence are variable and may be associated with specific clinicopathologic factors.

Citing Articles

CD44v6-mediated regulation of gastric cancer stem cells: a potential therapeutic target.

Chen H, Ling R, Lai J, Liu Z, Wang Z, Yang H Clin Exp Med. 2025; 25(1):80.

PMID: 40069421 PMC: 11897096. DOI: 10.1007/s10238-025-01611-4.


Development of a prognostic oxidative stress-immune-inflammation score and online calculators for predicting survival and recurrence in gastric cancer: a multicenter study.

Zheng H, Zheng H, Du X, Xu B, Hu M, Yu J Surg Endosc. 2025; .

PMID: 40050495 DOI: 10.1007/s00464-025-11596-6.


Evaluating survival outcomes and treatment recommendations in resectable gastric cancer.

Sabbagh S, Jabbal I, Herran M, Mohanna M, Iska S, Itani M Sci Rep. 2025; 15(1):2816.

PMID: 39843914 PMC: 11754744. DOI: 10.1038/s41598-024-82807-8.


Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline).

Kim I, Kang S, Choi W, Seo A, Eom B, Kang B J Gastric Cancer. 2025; 25(1):5-114.

PMID: 39822170 PMC: 11739648. DOI: 10.5230/jgc.2025.25.e11.


Mutant Pattern of p53 as a Feasible Predictor of Distant Metastasis Following Curative Gastrectomy for Advanced-stage Gastric Cancer.

An Q, Miao L, Wu J, Ma J J Cancer. 2025; 16(3):860-875.

PMID: 39781338 PMC: 11705056. DOI: 10.7150/jca.98563.


References
1.
Bonenkamp J, Hermans J, Sasako M, van de Velde C, Welvaart K, Songun I . Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999; 340(12):908-14. DOI: 10.1056/NEJM199903253401202. View

2.
McNEER G, VANDENBERG Jr H, DONN F, Bowden L . A critical evaluation of subtotal gastrectomy for the cure of cancer of the stomach. Ann Surg. 1951; 134(1):2-7. PMC: 1802668. DOI: 10.1097/00000658-195107000-00002. View

3.
Wanebo H, Kennedy B, CHMIEL J, Steele Jr G, Winchester D, Osteen R . Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993; 218(5):583-92. PMC: 1243028. DOI: 10.1097/00000658-199321850-00002. View

4.
Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V . Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999; 79(9-10):1522-30. PMC: 2362742. DOI: 10.1038/sj.bjc.6690243. View

5.
Dupont Jr B, COHN Jr I . Gastric adenocarcinoma. Curr Probl Cancer. 1980; 4(8):1-46. DOI: 10.1016/s0147-0272(80)80014-6. View